CDMO selection and funding signals

Cell therapy companies are tightening how they pick manufacturers as biotech investors keep backing a narrower set of platform bets. (elevate.bio) (ventureradar.com) A contract development and manufacturing organization is the outside factory and process team many drug startups hire to make clinical material. In cell therapy, that choice can decide whether a living-cell treatment reaches patients on schedule or runs into batch failures, delays, or regulatory findings. (elevate.bio) (lek.com) In a recent framework, ElevateBio Chief Technology Officer Mike Paglia said buyers should ask for first-time-right manufacturing rates, deviation data, operator tenure, and direct access to the manufacturing science, quality, and process-development staff running the program. He wrote that industry first-time-right rates “hover around 85-90%,” while “exceptional organizations consistently exceed 95%.” (elevate.bio) That checklist lands as cell therapy developers push into larger pipelines and more complex formats, including allogeneic products built from donor cells and next-generation engineered immune cells. L.E.K. Consulting said the cell therapy pipeline now exceeds 2,000 preclinical and clinical programs, and CDMOs have become “critical enablers” from early research through commercialization. (lek.com) The money side is sending a similarly selective signal. VentureRadar’s March 4, 2026 funding roundup pointed to investor interest in companies working on artificial-intelligence drug discovery, genetic-medicine delivery, and diagnostics, naming Antiverse, TileBio, Outpost Bio, GenEdit, Alveus Therapeutics, Xsensio, and BrainCheck. (ventureradar.com) VentureRadar said the common thread was not broad risk appetite but funding for tools that can speed research, improve delivery, or generate more standardized clinical data. Its roundup described targeted nanoparticles for RNA medicines as a “critical bottleneck” and said diagnostics and monitoring platforms are drawing attention as drug developers seek better real-world data. (ventureradar.com) That narrower appetite fits the broader funding backdrop. Colliers said 2024 life-sciences venture funding was $5.6 billion higher than 2023 and ranked as the fourth-best year on record, but still sat 37% below the 2021 peak. (colliers.com 1) (colliers.com 2) Geography is shifting, too, even if Boston/Cambridge and the San Francisco Bay Area still dominate the top of most cluster rankings. GEN said Boston/Cambridge retook the No. 1 U.S. biopharma-cluster spot in 2024, while R&D World’s 2024 ranking put Boston/Cambridge first, New York–New Jersey second, and the Bay Area third. (genengnews.com) (rdworldonline.com) At the same time, newer maps and real-estate analyses are giving more space to lower-cost regions with university talent and manufacturing capacity. BioSpace’s 2025 hotbed maps include BioMidwest alongside coastal centers, and JLL’s 2025 cluster analysis said U.S. hubs are now being judged across biomanufacturing, startup formation, talent, medtech, and artificial intelligence. (biospace.com 1) (biospace.com 2) (jll.com) For startups choosing where to build and whom to hire, the three signals line up: prove the factory can execute, raise money around a platform investors still want, and pick a hub that can supply talent without coastal pricing. (elevate.bio) (ventureradar.com) (jll.com)